TYAN Showcases HPC, AI and Storage Server Platforms Featuring 2nd Gen Intel® Xeon® Scalable Processors at SC19
19.11.2019 17:00:00 EET | Business Wire | Press release
TYAN®, an industry-leading server platform design manufacturer and a subsidiary of MiTAC Computing Technology Corporation, exhibits a broad selection of HPC, AI, storage and cloud server platforms that are optimized for enterprise and data center markets at SC19 through November 21st, Booth # 1601 in Denver’s Colorado Convention Center.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191119005008/en/
TYAN HPC Server Platforms Boost Performance with 2nd Gen Intel Xeon Scalable Processors for Enterprises and Data Centers (Photo: Business Wire)
“Data is the foundation of the new economy, and how organizations effectively move, store and process will help determine their level of success,” said Danny Hsu, Vice President of MiTAC Computing Technology Corporation's TYAN Business Unit. “By leveraging the 2nd gen Intel® Xeon® Scalable processors, TYAN’s leading portfolio of HPC, storage and cloud server platforms enable to help our customers accelerate innovation, drive business value, and bring products and services to market faster.”
TYAN HPC and Storage Server Platforms Boost Performance with 2nd Gen Intel Xeon Scalable Processors
TYAN’s HPC server platforms are built on the 2nd gen Intel Xeon Scalable processors with the addition of Intel® Deep Learning Boost technology and Intel® Optane™ DC persistent memory that enable to deliver higher performance for a range of HPC and AI applications. The new Thunder HX FT83-B7119 features high CPU-to-GPU bandwidth for various parallel workloads. The 4U system supports 10 double-width PCIe x16 slots for GPU deployment, a single-wide x16 networking card, up to 3TB of system RAM, and its front-loading 24 hot-swap, tool-less 3.5” drive bays enable easy access with simple, tool-free installation.
More HPC platforms on display include, Thunder HX FT77D-B7109 in a 4U two-socket design with integrated Intel® Omni-Path100 gigabit networking fabric for massively parallel workloads such as scientific computing and large-scale facial recognition; Thunder HX FT48T-B7105 in a 4U pedestal workstation design delivering maximum I/O to professional power users for 3D rendering and image processing; Thunder HX GA88-B5631 with high density and performance in a 1U single-socket chassis supporting 12 DIMM slots and 5 PCIe x16 slots for machine learning and artificial intelligence applications.
Powered by 2nd gen Intel Xeon Scalable processors, TYAN storage platforms offer a variety of tiered storage implementation scenarios for data centers and enterprises across a range of Thunder SX FA100-B7118, a 4U 100-bay high-capacity cold storage, Thunder SX TN76-B7102, a 2U server storage with 24 DDR4 DIMM slots and twelve 3.5” hot-swap drive bays for data virtualization and in-memory databases, and the Thunder SX GT62H-B7106, a 1U high-performance all-flash storage with 10 U.2 NVMe drive bays for extremely high speed data streaming applications.
The new Thunder SX GT90-B7113 is a 1U dual-socket high-density storage platform supporting twelve 3.5” hot-swap SATA drives (SAS drives are supported by configuration). mounted to a service drawer and four 2.5” hot-swap NVMe U.2 drive bays in a 35” chassis depth. The platform is designed for CSP server-based software-defined storage applications by allowing serviceability and density within the same server.
TYAN also showcases entry server platforms highlighting Intel® Xeon® E-2200 processors to offer professional-grade performance. The Thunder CX GT24E-B5556 is a 1U server optimized for cost-effective cloud gaming applications with support for up to 4 DDR4 DIMM slots, 1 double-width GPU card, and dual 10GBase-T Ethernet ports; the Thunder CX GX38-B5550 is a 1U compact sever with sub-400mm deep chassis and support for two 3.5" internal SATA drive bays for edge computing.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191119005008/en/
Contact information
MiTAC Computing Technology Corporation/ TYAN Business Unit
Fenny Chen
fenny.chen@tyan.com.tw
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom